Kornimate/medical-research-clean huggingface dataset:
trial to learn about the study medicine (pf-07081532) and rybelsus in people with type 2 diabetes and separately pf-07081532 in people with obesity

Conditions: Diabetes Mellitus; Obesity

Summary: the purpose of this study is to find out if pf-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called rybelsus. those in the obesity part of the study, will receive either active study drug or placebo. the study will last for about 36 weeks except for the first 25% of the participants that enter in which case the study will last for approximately 48 weeks. during this time there will be visits every 4 weeks with phone calls in between.


Eligibility criteria:
inclusion criteria: t2dm * t2dm inadequately controlled with metformin * bmi ≥23.0 kg/m2 (≥20.0 kg/m2 in japan) * hba1c of 7% to 10% (53-86 mmol/mol) * fpg ≤270 mg/dl (15 mmol/l) obesity * bmi ≥30.0 kg/m2 * hba1c ≤6.4% (47 mmol/mol) * fpg ≤126 mg/dl (7 mmol/l) exclusion criteria: * any of the following: active/current, symptomatic gallbladder disease; history of pancreatitis in the prior 2-months;history of type 1 diabetes mellitus, or secondary forms of diabetes; any condition affecting drug absorption; medical history of active liver disease (other than non-alcoholic hepatic steatosis) * use of pharmacological agents with approved indication for weight loss * t2dm:use of any agent (other than metformin)for the explicit purpose of glycemic control;history of diabetic ketoacidosis;proliferative retinopathy or maculopathy requiring acute treatment; * obesity: previous or planned weight reduction surgery; major depressive disorder or other severe psychiatric disorders; any lifetime history of a suicide attempt; phq-9 score ≥15; response of "yes" to question 4 or 5, or on any suicidal behavioral question on the c-ssrs * clinically significant cardiovascular conditions * uncontrolled blood pressure * personal or within first-degree relative family history of mtc or men2 * other medical or psychiatric condition that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study * any of the following central lab results: fasting c-peptide \ uln or t bili \>1.5x uln except when participants have a history of gilbert syndrome ; tsh \>1.5x uln or \ uln; serum amylase or serum lipase \>uln; egfr \<45 ml/min/1.73 ; active hepatitis b, or hepatitis c; a positive urine drug test for illicit drugs

Keywords: diabetes mellitus obesity
once-a-day pregabalin for partial seizures

Conditions: Partial Seizures; Epilepsies, Partial

Summary: approximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs. the present study will compare the efficacy of two different dosages of pregabalin cr dosed once daily as compared to placebo, when used as adjunctive therapy in subjects requiring adjunctive therapy for partial onset epilepsy, using a randomized, parallel group design.


Eligibility criteria:
inclusion criteria: * diagnosis of epilepsy with partial onset seizures (seizures may be simple or complex, with or without evolution into a bilateral, convulsive seizure) * currently taking 1 to 3 anti-epilepsy medicines (aeds) at stable dosages, and who have taken at least 2 prior (or ongoing) aeds exclusion criteria: * primary generalized seizures (for example, absence, myoclonic seizures or lennox-gastaut syndrome) * status epilepticus within one year prior to screening

Keywords: partial epilepsy partial seizures epilepsy seizures adjunctive therapy intervention controlled-release placebo-controlled seizure
the prevalence of irritable bowel syndrome using rome iv criteria in medical student and the related factors

Conditions: IBS - Irritable Bowel Syndrome

Summary: a cross-sectional study of 350 medical student universitas indonesia from first grade until fifth grade was done during november-december 2016. this study used stratified randomized sampling. the rome iv criteria was used for diagnosing ibs. questionnaire-guided interview was applied to all subjects.

a cross-sectional study of 350 medical student universitas indonesia from first grade until fifth grade was done during november-december 2016. this study used stratified randomized sampling. the rome iv criteria was used for diagnosing ibs. questionnaire-guided interview was applied to all subjects. a bivariate analysis was done to know the relationship between ibs and its related factors using chi-square, unpaired t-test, and their alternatives. multivariate analysis was done using logistic regression test

Eligibility criteria:
inclusion criteria: * age of participant \>= 15 years * volunteer to participate in study exclusion criteria: * red flag symptoms: febrile, vomiting, rectal bleeding, weight lost * diagnosed as having inflammatory bowel disease * peptic ulcer drug consumption * history of gastrointestinal surgery

Keywords: ibs, rome iv criteria, anxiety
propanolol and red cell adhesion non-asthmatic children sickle cell disease

Conditions: Sickle Cell Disease

Summary: propanolol is a beta blocker which has been found to inhibit the ability of epinephrine to upregulate sickle red cell adhesion to laminin and endothelial cells in vitro. the purpose of this pilot study is to administer one dose of propanolol to children with sickle cell disease and to measure pre and post dose red cell adhesion. the hypothesis is that a single dose of propanolol will decrease red cell adhesion to laminin and endothelial cells as compared to baseline.

a similar pilot study has already been conducted in adults and is now being tried in children to gather preliminary data for a grant submission. no safety issues were found in the adult pilot study. this study will evaluate the effect of different doses of propanolol. the risks of this study involve the risks of three (3) blood draws and the risks of propanolol. in order to minimize the risks children with sickle cell disease and asthma will be excluded because asthma is a contraindication to the use of propanolol. in addition, patients will not be hypertensive or bradycardic.

Eligibility criteria:
inclusion criteria: 1. diagnosis of hbss or hbsbeta0thal 2. age 10-17 years 3. weight 30kg or greater 4. hb 7mg/dl or greater 5. informed consent exclusion criteria: 1. history of vaso-occlusive crisis during the past 6 weeks, or history of transfusion during the past 3 months. 2. pregnancy 3. history of heart failure, myocardial infarction, asthma, bradyarrythmias, hypotension, thyroid disease, diabetes, renal insufficiency 4. concurrent medications: any antihypertensive medication, diuretics, thyroid replacement medications, any arrythmia medication, insulin, hypoglycaemic medication 5. history of allergy to sulfonamides 6. elevated bun or creatinine

Keywords: sickle cell disease propanolol red blood cell adhesion
survey and cognitive behavior therapy for chronic fatigue syndrome/myalgic encephalomyelitis

Conditions: Chronic Fatigue Syndrome; Myalgic Encephalomyelitis; Fatigue; Pain

Summary: the purpose of this study is to analyze income variables in chronic fatigue syndrome/myalgic encephalomyelitis, and to analyze the effect of short vs. long cognitive behaviour therapy.


Eligibility criteria:
inclusion criteria: * patients referred to st.olav hospital, trondheim * fulfil the fukuda criteria for cfs/me. exclusion criteria: * pregnant patients

Keywords: cbt fukuda criteria mental functioning physical functioning
maternal serum vascular endothelial growth factor in pregnant women with foetal growth restriction

Conditions: Foetal Growth Restriction

Summary: in this study we explore to explore the role of maternal serum vascular endothelial growth factor (vegf) in pregnancies complicated by foetal growth restriction.

small-for-gestational age (sga) is defined as an estimated foetal weight (efw) or abdominal circumference (ac) less than the 10th centileand severe sga as an efw or ac less than the 3rd centile. foetal growth restriction refers to failure of the foetus to achieve its predetermined growth potential for various reasons.foetus with foetal growth restriction (fgr) greatly contributes to perinatal mortality and short- and long-term morbidity. there is a 3-10 fold increase in perinatal mortality in pregnancies complicated by this fgr .the incidence of fgr in newborns ranges between 3 and 7% of the total population .fgr is thought to stem from placental hypoxia-induced vasoconstriction of the fetoplacental vessels, leading to placental hypoperfusion and thus fetal undernutrition. however, the effects of hypoxia on the fetoplacental vessels have been surprisingly little studied.vascular endothelial growth factor (vegf) is one of the factors that take part in placental angiogenesis. it is highly expressed during embryonic and foetal development..angiogenesis involves the branching of new microvessles from pre-existing larger blood vessels.angiogenesis plays a role in the development of the villous vasculature and the formation of terminal villi in human placenta. iugr occurs as a result of the failure of elongation, branching and dilatation of the capillary loops and of terminal villous formation.

Eligibility criteria:
inclusion criteria: * age 20-40 years * gestational age 28-36 weeks * fetal growth restriction * patient consents to the procedure. * bmi 20-30 exclusion criteria: * preeclampsia * diabetes mellitus * fetal congenital anomalies

Keywords: serum vegf, fgr
high-flow nasal cannula oxygen versus conventional oxygen therapy after pulmonary lobectomy

Conditions: Respiratory Insufficiency; Lung Cancer

Summary: the primary objective of this study is to evaluate the effect of early application of nasal high flow oxygen therapy after pulmonary lobectomy on the incidence of postoperative hypoxemia

high-flow nasal cannula oxygen (hfnco) treatment has been showed to have several clinical advantages compared with conventional oxygen therapy. currently, no reports have described the effects of hfnco in postoperative patients after thoracic surgery. the primary objective of this study is to determine the incidence of postoperative hypoxemia (defined as a pao2/fio2 ratio \<300) in patients with lung cancer after pulmonary lobectomy. in the postoperative period after extubation, patients will be randomly assigned to either: 1. standard oxygen therapy group (control group) or 2. hfnco group (study group). in the control group, patients will receive oxygen treatment by means of a conventional face mask, with a level of fraction of inspired oxygen (fio2) set to maintain peripheral oxygen saturation (spo2) = 92% - 98%. patients in the study group will be given hfnco treatment with a gas flow level = 50 l/min and a fio2 set to maintain peripheral oxygen saturation (spo2) = 92% - 98%. after 48 hours from study entry, all patients will be evaluated for possible interruption of oxygen treatment on the basis of their clinical conditions.

Eligibility criteria:
inclusion criteria: * planned pulmonary lobectomy for lung cancer exclusion criteria: * age \<18 years * patient refusal * body mass index ≥35 kg/m2 * sleep apnea syndrome * tracheostomy * home oxygen therapy * pregnancy
streamlining care for patients with compression neuropathies: the carpal tunnel plus pathway

Conditions: Carpal Tunnel Syndrome (CTS)

Summary: the goal of this clinical trial is to assess the impact of a new care pathway (the carpal tunnel plus pathway) in patients with carpal tunnel syndrome. the main questions it aims to answer are: 1. what was the effect of the carpal tunnel plus pathway on wait times between each step of the care pathway (e.g. from referral to initial consult, from initial consult to surgical consult, etc.)? 2. how satisfied are patients with the care they received through the carpal tunnel plus pathway? researchers will compare wait times pre- and post- pathway implementation to see if there was any change. participants will be asked to complete a short patient satisfaction survey.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * referred to the vancouver general hospital neuromuscular disease unit or st. paul's hospital with a confirmed diagnosis of carpal tunnel syndrome * ability to understand english exclusion criteria: * inability to provide informed consent

Keywords: carpal tunnel syndrome patient satisfaction care pathway
study to evaluate efficacy and tolerance of r-gemox in dlbcl and mcl

Conditions: Aggressive Lymphoma; Diffuse Large B-cell Lymphoma; Mantle Cell Lymphoma

Summary: the purpose of this study is to determine efficacy of rituximab, gemcitabine, oxaliplatin and dexametasone (r-gemox) chemotherapy schedule.

the purpose of this study is to determine efficacy (overall response rate (orr) and complete response) tolerance and toxicity of rituximab, gemcitabine, oxaliplatin and dexametasone (r-gemox) chemotherapy schedule.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. dlbcl and mcl diagnosed patients in primary resistance or relapsed not eligible for intensification chemotherapy followed by autologous stem cell transplantation (asct) for age, comorbidity or previous asct. 3. any ipi or ecog, capable of understanding the nature of the trial. 4. writtern informed consent. exclusion criteria: 1. nursing pregnant or lactation period women, or fertile age adults not using effective contraceptive method. 2. cns lymphoma patients. 3. patients with severa renal (creatinine\> 2,5 unl) or hepatic (bilirrubin or alt/ast\> 2,5 unl) impairement not provided by the same disease 4. hiv positive patients. 5. serious psychiatric diseases patients that could interfere with their skill to understand the study (including alcoholism or drug addiction). 6. murine proteins or any other component of the medicines of the study hypersensitivity patients. 7. patients who have received more than 2 therapeutic previous lines. (for previous asct patients, induction and conditioning for the taph treatment is considered a single line therapy).
cardiac output monitoring to predict pre-eclampsia and restricted growth (compare)

Conditions: Fetal Growth Retardation; Pre-Eclampsia

Summary: pre-eclampsia (pet) and fetal growth restriction (fgr) are common complications of pregnancy that affect up to 15% of pregnancies in the uk. these conditions can have potentially devastating consequences to mothers and babies in pregnancy. pre-term birth, that is often medically indicated to treat severe pet and fgr can cause cerebral palsy, breathing difficulty, developmental delay and even death in affected babies. mothers who suffer from pet are at risk of seizures, strokes, multi-organ failure and future chronic hypertension. it is now thought that pet and fgr may result from poor adaptation of the maternal cardiovascular system to normal pregnancy. this project aims to study the patterns within the maternal cardiovascular system and haemodynamic profile in women who are at high risk of pet and fgr by using non-invasive methods to gather information about the functions of their hearts and major blood vessels. the investigators hope to elucidate the patterns that may offer an early warning to mothers who may develop pet and whose fetuses may be growth restricted. this would be an opportunity to more closely monitor, modify risk factors and treat earlier women who develop these conditions. women who are at a high risk of pet and fgr as stipulated in the relevant royal college of obstetrics \& gynaecology and national institute of clinical excellence guidelines and who give their consent will be eligible for the study.


Eligibility criteria:
inclusion criteria: * pregnant women aged ≥18 at time of conception * case subjects are at high risk of pet by nice guidelines ( ≥1 high risk factor or \>1 moderate risk factor) or high risk of sga by rcog guidelines (≥1 major risk factor or ≥3 minor risk factors). control subjects do not meet this criteria exclusion criteria: * maternal age \<18 years of age at time of booking * fetal structural or genetic abnormality * multiple pregnancy * known underlying maternal cardiac condition
home-based visual-motor training program on kindergarteners

Conditions: Developmental Delay; Preterm Children

Summary: the study aims to investigate the feasibility and effectiveness of the traditional and computerized home-based visual-motor training programs on at-risk kindergarteners.

the purpose of this project is to investigate the feasibility and effectiveness of home-based traditional visual-motor activities and tablet games on fine motor, visual perception, visuo-motor integration, handwriting performance, and adaptive behaviors of at-risk kindergarteners. at-risk kindergarteners will be randomized into the three groups: control, traditional, and tablet groups. in addition to regular early intervention, children in the traditional and tablet group will receive home-based visuo-motor training program with their parents. children in the control group will only receive regular intervention during the study period.

Eligibility criteria:
inclusion criteria: 1. either visual perception or fine motor score below the norm average 2. can follow instruction and complete the entire tests exclusion criteria: 1. visual or hearing problems that cannot be corrected to be normal 2. a diagnosis of significant neurological, muscular, and skeletal system disorders (e.g., cerebral palsy) 3. a diagnosis of moderate or severe intellectual disabilities 4. taking medication to control seizure or improve learning abilities

Keywords: visual motor, kindergarten children, developmental delay
electrical muscle stimulation on muscle stiffness and functional capacity in post-menopausal women

Conditions: Electric Stimulation Therapy; Frailty; Women

Summary: the aim of this study will be to determine the effects of different electrical muscle stimulation protocols on muscle stiffness and functional capacity in post-menopausal women. a randomized controlled clinical trial will be carried out. a total sample of 27 post-menopausal women will be recruited and divided into 3 groups which received high-frequency electrical muscle stimulation during 8 weeks, low-frequency electrical muscle stimulation during 8 weeks or no-intervention (control group). outcome measurements will be stiffness assessed by sonoelastography and functional capacity assessed by the 30 seconds chair-stand test before and after 8 weeks interventions.


Eligibility criteria:
inclusion criteria: * post-menopausal women exclusion criteria: * arrhythmias * diabetes * smokers
ultrasound and attenuation imaging

Conditions: Non-Alcoholic Fatty Liver Disease; Non Alcoholic Fatty Liver; Non-alcoholic Steatohepatitis; Steatosis of Liver

Summary: fatty liver disease affects almost a 3rd of the united kingdom (uk) population. currently, this is being investigated using a type of mri scan that reports how fatty or not a person's liver is, with a liver fat score, but many patients cannot have this type of scan due to time, cost or because they have a condition which makes magnetic resonance imaging (mri) an unsafe scan for them to have. an ultrasound scan is cheaper, faster and safer for a wider variety of patients. new developments in ultrasound technology mean that instead of a sonographer, or ultrasound operator, deciding whether your liver is fatty or not based on what they see on the scan, the ultrasound machine gives a liver fat score. this study will look at the relationship between the sonographers' view on how fatty the liver is, compared with the liver fat score given by the new development in ultrasound technology.

non-alcoholic fatty liver disease (nafld) affects almost a 3rd of the population of the uk and current best practice is to evaluate this using magnetic resonance imaging proton density fat fraction (mri pdff), however, this is inaccessible to many patients due to limited availability, cost and a large exclusion criteria. ultrasound offers an affordable, faster and more inclusive method of liver evaluation but only subjective assessment of fatty liver disease until a recent development- attenuation imaging (ai). attenuation imaging gives a numerical score for fatty liver disease. attenuation imaging has previously only been compared to mri pdff, however, when many patients do not have mri pdff it is essential to compare it to common practice, conventional ultrasound. this study aims to assess the agreement between conventional ultrasound assessment of the liver and ai using a cross-sectional method. convenience sampling will be used to select 95 participants who will have their ai score carried out alongside their routine ultrasound scan with the sonographer blinded to the ai results. the inter-rater agreement will be determined using kappa statistics. the results will demonstrate the strength of relationship between the two methods. a strong agreement between the two may facilitate further investigation into the uses of ai, such as use as a teaching tool or in aiding decisions in cases that sonographers find more difficult to assess such as those patients with a high bmi.

Eligibility criteria:
inclusion criteria: * 18 years old or over * general practitioner (gp) and outpatients (op) referral * nafld, unknown, diabetes, other metabolic disease exclusion criteria: * younger than 18 years old * inpatients * known large liver masses * poor visualisation of the liver due to body type or anatomy.
skin incision skewness at cesarean section

Conditions: Cesarean Section

Summary: skin incision skewness, incision length on both sides of the midline and patient's perception of the scar after cesarean section will be compared between the following two groups: (1) drawing of an incision line prior to skin incision and (2) no drawing of an incision line.

some aspects of the surgical techniques employed during cesarean section have already been evaluated in regards to possible improvements of cosmetic outcome, such as the use of different skin closure materials or whether subcutaneous fat suture closure leads to better results than non-closure. another point to be considered is the skewness of the scar. many surgeons make the skin incision based on their experience without prior measurement and drawing of an incision line. however, following a predefined incision line may reduce the rate of skew incisions. therefore, this study aims to compare these two approaches to the skin incision. participating women will be recruited at the department of obstetrics and gynecology of the medical university of vienna. they will be included into the study after written informed consent and will be randomized into one of the two groups (drawing of an incision line prior to skin incision versus no drawing of an incision line) on the day of cesarean section. skewness of the skin incision in each group will be assessed after cesarean section. furthermore, it will be determined whether there are any differences in the incision length on both sides of an imaginary line from the umbilicus to the clitoris between these two techniques. additionally, patient's perception of the scar before discharge from hospital will be assessed.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * first cesarean section exclusion criteria: * performance of an acute cesarean section * previous cesarean section * body mass index \> 35 kg/m²

Keywords: cesarean section skin incision skewness line drawing